A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Microsatellite Instability-High (MSI-H) Solid Tumors|Cutaneous Melanoma|Pancreatic Cancer|Breast Cancer (HR+HER2-)
Interventions: DRUG: LY3300054|DRUG: Ramucirumab|DRUG: Abemaciclib|DRUG: Merestinib|DRUG: LY3321367
Sponsor: Eli Lilly and Company